x
ServiziMenu principaleHome
You are here: Home > Education > Future Events > 3rd ESO-ESMO-RCE Preceptorships & Clinical Update on Rare Adult Solid Cancers
Print

3rd ESO-ESMO-RCE Preceptorships & Clinical Update on Rare Adult Solid Cancers

01.12.2018  -  03.12.2018

Milan, Italy

ADVANCED COURSES & SEMINARS

Rare genito-urinary cancers, Rare gynaecological cancers, Rare head and neck cancers, Rare tumors, Sarcoma

*Third party registration should be used if you are requesting an individual registration for someone who is not you.
Please note that website registration under your name will be needed before registering someone else to this event.

Description

Chairs: J.Y Blay, FR - P.G. Casali, IT - R. Stahel, CH


Rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. This Course is aimed at dealing with them on an annual basis with the ultimate goal to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence. This course has been conceived in the context of the European Reference Network on Rare Adult Solid Cancers (EURACAN) and the Joint Action on Rare Cancers of the European Union (JARC). The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with the networking activities of EURACAN and the networking educational efforts that are ongoing within EURACAN, JARC and Rare Cancers Europe.

The RARECARE project provided a definition and a list of rare cancers, the following being the 10 “families” of rare adult solid cancers:

• Rare skin cancers and non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Sarcomas
• Digestive rare cancers
• Rare urological and male genital tumors
• Central nervous system neoplasms
• Head and neck cancers

FORMAT
The third edition of this joint initiative, which involves ESO, ESMO and Rare Cancers Europe, will combine:

Day 1 - Parallel Preceptorships on the majority of rare adult solid cancers. Participants will be invited to select 3 preceptorships they would like to attend.

Day 2 and 3 - Clinical updates on the main innovations from the 10 families of rare adult solid cancers.

Preceptorships have been conceived by looking at the educational needs of clinical oncologists willing to open up to rare adult solid cancers as well as patient advocates. They will be multidisciplinary and clinically oriented.

The Clinical update sessions are designed to address the needs of oncologists wanting to catch up with the advancements in the treatment of rare adult solid cancers.

Attendees may select whether to attend all three days or only the 2-day Clinical Update.

The course is an ESO-ESMO-RCE joint event                    
RCE         ESMO          
Held in collaboration with         In the framework of
 INT                




Invited faculty

INVITED FACULTY
M. Angi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE
J.Y. Blay, Centre Léon Bérard, Lyon, FR
A. Berruti, ASST Spedali Civili, Brescia, IT
J. Capdevila, Vall d'Hebron University Hospital, Barcelona, ES
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A.P. Dei Tos, Azienda ULSS9, Treviso, IT
F. De Lorenzo
, European Cancer Patient Coalition, Brussels, BE
M. Deraco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
N. Fazio, Istituto Europeo di Oncologia, Milan, IT
M. Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
N. Girard, Hopital Louis Pradel, Bron, FR
J.A. Gietema
, University Medical Center, Groningen, NL
R. Glynne-Jones, Mount Vernon Centre for Cancer Treatment, London, UK
C. Grau, Aarhus University Hospital, Aarhus, DK
A. Gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
C. Lebbé, Hopital St. Louis, Paris, FR
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
D. Lorusso, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
V. Mazzaferro, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Newbold, The Royal Marsden NHS Foundation Trust, London, UK
N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
U. Pastorino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. Peccatori
, European School of Oncology, Milan, IT
F. Raspagliesi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
J. Sacco, The Clatterbridge Cancer Centre, Liverpool, UK
M. Seckl
, Hammersmith Campus, London, UK
C. Simon, Université de Lausanne, CHUV Lausanne, CH
R. Soffietti, AOU San Giovanni Battista, Torino, IT
S. Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R.A. Stahel, Cancer Center University Hospital, Zurich, CH
D. Talbot, Oxford University Hospital, Oxford, UK
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Van den Bent, Erasmus MC Cancer Institute, Rotterdam, NL
M. Wartenberg, Sarcoma Patients EuroNet, Wölfersheim, DE

General information

ORGANISING SECRETARIAT
European School of Oncology
Rare Tumours Programme
c/o Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1
20133 Milano - Italy
Fax +39 0223902531
Email: raretumours@eso.net

ACCREDITATION
Application for CME recognition will be submitted to the European Accreditation Council for Continuing
Medical Education (EACCME) and to the Italian CME accreditation system.
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).

Information on the status of the applications can be obtained from the organising Secretariat.

BADGE
The badge is the only official evidence of registration and should be worn at all times during the event.

INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation during the Course. Participants are advised to take out their own personal and travel insurance.

OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.

IMPORTANT DEADLINES

Abstracts: insert the date  
Travel grants: insert the date  
Early registration by: 31 October 2018  
Late registration from: 01 November 2018  
Save the event date: 01 December 2018  

 

 

Travel Grant

TRAVEL GRANTS (FOR PHYSICIANS AND FULL PARTICIPATION ONLY)
Travel grants are given for full participation (three day course) on a competitive basis thanks to the support of Rare Cancers Europe. Priority will be given to younger candidates and low/middle income Countries.
To submit the Travel Grant application please complete the online form (available at the bottom of this page) and upload your Curriculum vitae and motivation letter by 1st October.
All applicants will be contacted by 15th October. Those applicants who are not selected for a grant will still be able to register with the early rate fee (deadline: 31st October).

Successful Travel Grant applicants coming from the following countries will receive:

Italy € 500 (plus free registration)
Southern and Western Europe € 700 (plus free registration)
Northern, Central and Eastern Europe € 800 (plus free registration)
Other and overseas € 1000 (plus free registration)

SUBMIT HERE

Registration

PARTICIPANT’S PROFILE
• Medical degree
• Specialization/residency in medical oncology, radiation oncology, surgical oncology or equivalent
• Fluency in English

REGISTRATION
The online registration at the top of the page is related ONLY to the three-day course.
If interested in participating in the Clinical Update course only (2 days), please refer to this link for online registration.

Registration to the full course (3 days) should be completed by sending the preceptorship form (downloadable HERE) to raretumours@eso.net immediately after online registration.

PATIENT ADVOCATES
will be selected by Rare Cancers Europe. For information rarecancerseurope@esmo.org

 
Registration fees:

 

 Early
(by 31 October)

 Late
(From 1 November)

Registration fee (full participation rate - 3 days)
 EUR 250
 EUR 300
Club ESO and ESMO Members (full participation rate)  EUR 200
     
Registration fee (Clinical Update - 2nd and 3rd day)  EUR 200 EUR 250  
Club ESO and ESMO Members (Clinical update)  EUR 160

Rates are indicated in Euro and include VAT.
Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme.

CANCELLATION OF REGISTRATION OR REPLACEMENT
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee minus handling charges of EUR 100 will be refunded within two months from notification, provided that the cancellation is received by ESO before 9 November. Communication of replacements will be possible up until 15 November.

Programme

 PRECEPTORSHIPS ON RARE ADULT SOLID CANCERS

 
1 December

8:30   Registration and coffee entry    
8:50   Welcome
P.G. Casali, IT
INTRODUCTION (plenary)
9:00   Epidemiology and rare cancer networking
A. Trama, IT
9:30   The pathologic diagnosis
A.P. Dei Tos, IT
10:00   Clinical decision making in RC
P.G. Casali, IT
    Coffee break
BREAKOUT PRECEPTORSHIP 1
11:00   Sarcomas
S. Bielack, GR - J.Y. Blay, FR - P.G. Casali, IT - A. Gronchi, IT
11:00   Rare urogenital cancers
J.A. Gietema, NL - N. Nicolai, IT
11:00   Digestive rare cancers
V. Mazzaferro, IT - R. Glynne-Jones, UK - F. De Braud, IT
13:00   Lunch
BREAKOUT PRECEPTORSHIP 2
14:00   Rare female genital cancers
D. Lorusso, IT - I. Ray-Coquard, FR - F. Raspagliesi, IT - M. Seckl, UK
14:00   Rare thoracic cancers
R.A. Stahel, CH - M. Garassino, IT - N. Girard, FR - U. Pastorino, IT
14:00   Rare skin tumors and uveal melanoma
C. Lebbé, FR - L. Licitra, IT - M. Angi, IT - J. Sacco, UK
    Coffee break
BREAKOUT PRECEPTORSHIP 3
16:30   CNS tumors
R. Soffietti, IT - M. van den Bent, NL
16:30   Neuroendocrine tumors
D. Talbot, UK - V. Mazzaferro, IT
16:30   Head and neck cancers w/ Thyroid cancer
K. Newbold, UK - J. Capdevila, ES - C. Simon, CH

 
CLINICAL UPDATE on RARE ADULT SOLID CANCERS

 2 December

8:30   Registration
9:00   Welcome from ESO and ESMO
F. Peccatori IT - R.A. Stahel, CH
UPDATE ON RARE THORACIC CANCERS
Moderators: M. Garassino IT, RA Stahel CH
9:10   Mesothelioma
R.A. Stahel, CH
9:30   Thymic tumors
N. Girard, FR
9:50   Discussion
UPDATE ON NEUROENDOCRINE TUMORS
Moderators: D. Talbot, UK - F. De Braud IT
10:10   Thoracic neuroendocrine tumors
D. Talbot, UK
10:30   Gastroenteropancreatic neuroendocrine tumors
N. Fazio, IT
10:50   Discussion
10:10   Coffee break
UPDATE ON DIGESTIVE RARE CANCERS
Moderators: R. Labianca, IT - V. Mazzaferro, IT
11:40   Biliary tumors
F. de Braud, IT
12:00   Anal carcinoma
R. Glynne-Jones, UK
12:20   Peritoneal mesothelioma & pseudomyxoma peritonei
M. Deraco, IT
12:40   Discussion
13:00   Lunch
UPDATE ON CNS TUMORS
Moderators: R. Soffietti, IT - M. van den Bent, NL
14:00   Gliomas
R. Soffietti, IT
14:20   Rare CNS tumors
M. van den Bent, NL
14:40   Discussion
UPDATE ON SARCOMAs
Moderators: P.G. Casali, IT - A. Gronchi, IT
15:00   Adult soft tissue sarcomas
P.G. Casali, IT
15:20   GIST
J.Y. Blay, FR
15:40   Ewing sarcoma and Osteosarcoma
S. Bielack, DE
16:00   Rare bone sarcomas
S. Stacchiotti, IT
16:20   Discussion
16:30   Coffee break
UPDATE ON RARE UROGENITAL CANCERS
Moderators: J.A. Gietema, NL - N. Nicolai, IT
17:00   Testicular cancer
J.A. Gietema, NL
17:20   Discussion
UPDATE ON RARE FEMALE GENITAL CANCERS
Moderators: D. Lorusso, IT - F. Peccatori, IT
17:30   Non-epithelial ovarian tumors
I. Ray-Coquard, FR
17:50   Trophoblastic tumors
M. Seckl, UK
18:10   Discussion

 

 3 December

UPDATE ON RARE SKIN TUMORS & UVEAL MELANOMA
Moderators: M. Angi, IT - C. Lebbé, FR
9:00   Uveal melanoma
M. Angi, IT
9:20   Merkel cell carcinoma
C. Lebbé, FR
9.40   Discussion
UPDATE ON HEAD & NECK CANCERS
Moderators: C. Grau, DK - L. Licitra, IT
10:00   Laryngeal & hypopharyngeal carcinoma
L. Licitra, IT 
10:20   Oropharyngeal carcinoma
C. Grau, DK
10:40   Coffee break
11:00   Nasopharyngeal carcinoma & sinonasal cancers
L. Licitra, IT
11:20   Salivary gland tumors
L. Licitra, IT
11:40   Discussion
UPDATE ON ENDOCRINE GLAND TUMORS
Moderator: L. Licitra, IT  
12:00   Adrenal cancer
A. Berruti, IT
12:20   Thyroid cancer
J. Capdevila, ES
12:40   Discussion
13:00   Lunch
14:00 RARE CANCERS IN EUROPE
Moderators: P.G. Casali IT - F. De Lorenzo IT - M. Wartenberg, DE
15:30   Closing remarks, with a view to networking…
P.G. Casali, IT

 

Follow us